#United States #Menlo Park #cancer detection #GRAIL Inc #Galleri Test

GRAIL, Inc. Reports Second Quarter 2026 Financial Performance

GRAIL, Inc. (Nasdaq: GRAL), a pioneering healthcare company focused on early cancer detection, presented its financial results for the second quarter of 2026, highlighting impressive growth in its Galleri multi-cancer early detection test, despite facing significant operating losses.

Key Financial Highlights

For the quarter ending June 30, 2026, GRAIL achieved:

• - Total Revenue: Reached $44.7 million, a 26% increase compared to the same period last year. This growth is attributed primarily to the increased uptake of its Galleri test.
• - Galleri Test Revenue: Grew by 24% year-over-year to $42.6 million, marking a substantial performance in a challenging market.
• - Galleri Test Volume: Exceeded 61,000, reflecting a 35% rise year-over-year. The test volumes for the first half of 2026 also showed robust growth, soaring by 42% to more than 117,000 tests performed.

Despite these positive trends, GRAIL reported a net loss of $110.2 million for the quarter, though this figure represents a slight improvement from the losses incurred in the previous year. Additionally, the company recorded a gross loss of $12.6 million but was able to report an adjusted gross profit of $21.6 million, illustrating the underlying health of its operations.

Clinical Advancements

GRAIL's leadership emphasized their commitment to clinical excellence, showcasing data from two significant studies, the NHS-Galleri and PATHFINDER 2 trials, at the 2026 American Society of Clinical Oncology Annual Meeting. Key findings from these studies include:

• - The NHS-Galleri trial demonstrated a reduction in late-stage cancer diagnoses, with an impressive 22% decrease in specific aggressive cancers during second round screenings.
• - Overall, the combination of Galleri and standard care screenings resulted in a fourfold increase in cancer detection, further affirming the test's utility in identifying cancers at earlier stages when they are more potentially curable.

The PATHFINDER 2 study yielded similarly encouraging results. Findings suggested that when Galleri was added to regular screening protocols, nearly 60% of cancers were detected, yielding a staggering increase in the efficacy of cancer screening methodologies.

Strategic Collaborations and Future Prospects

In keeping with its growth trajectory, GRAIL secured a $110 million equity investment from Samsung CT Corporation, targeting further commercialization of the Galleri test across South Korea and potentially into other Asian markets like Japan and Singapore. This partnership aligns with GRAIL's vision to broaden its impact in cancer detection on a global scale.

GRAIL also anticipates an FDA advisory committee review of its Premarket Approval (PMA) application for the Galleri test in the fall. The application is backed by comprehensive data from its extensive clinical trials, which positions GRAIL to solidify its role in the intersection of healthcare innovation and cancer prevention.

Conclusion

As GRAIL continues to navigate its growth strategy amidst financial challenges, the company's focus remains on leveraging advanced technologies and solid clinical evidence to improve cancer screening effectiveness. The substantial rise in Galleri test utilization and revenue growth validate GRAIL's unique approach in the healthcare landscape, aiming ultimately to reduce cancer mortality through early detection.

Stay tuned for more updates as GRAIL progresses toward its ambitious goals in redefining cancer screening protocols and outcomes.